Reply to J.M. Kolesar et al, J.S. Bates et al, and T.C. Knepper et al

摘要

We are gratified that our commentary resonated enough with the intended audience to prompt multiple groups to respond with their concurring perspectives that our concerns represent a major issue. Each group shared their solutions and ensuing successes of their specific programs from the challenge of translating practical recommendations from biomarker testing results into practical management for oncology clinicians. What is most striking is the diversity of clinical settings represented-a large, tertiary care cancer center in an urban area, a statewide program serving Kentucky's predominantly rural Appalachian region, and the Veteran's Administration (VA) system on a nationwide scale. Interestingly, each of these programs has independently arrived at a solution centered on oncology pharmacists as key facilitators of molecular tumor boards (MTBs) that have successfully delivered practical guidance to very different clinician populations.